Skip to main content
. 2015 Jan 5;35(3):693–701. doi: 10.3892/ijmm.2015.2062

Figure 3.

Figure 3

specificity protein 1 (Sp1) is involved in transforming growth factor-β1 (TGF-β1)-induced high mobility group A1 (HMGA1) promoter activity in breast cancer. (A and B) Effects of TGF-β1 on HMGA1 promoter activity. MCF-7 cells and MDA-MB-231 cells were transfected with the HMGA1 promoter/vector containing luciferase or with the empty control vector, PGL4.1, using Lipofectamine 2000 for 24 h, and the cells were treated with the indicated concentrations of TGF-β1. Twelve hours later, the cells were subjected to luciferase activity assay (n=3). (C) Binding of Sp1 and p-Sp1 (Thr453) to HMGA1 promoter was enriched following 12 h of TGF-β1 treatment in electrophoretic mobility shift assay (EMSA) (Materials and methods). Lane 1, probe; lane 2, probe + nucleic protein complex; lane 3, probe + nucleic protein complex + cold probe; lane 4, probe + nucleic protein complex + Sp1 antibody(−TGF-β1); lane 5, probe + nucleic protein complex + Sp1 antibody(+TGF-β1); lane 6, probe + nucleic protein complex +p-Sp1 antibody(-TGF-β1); lane 7, probe + nucleic protein complex + p-Sp1 antibody (+TGF-β1). *P<0.01, compared with the group not treated with TGF-β1.